SCHEMBL11027119

SCHEMBL11027119

Cc1ccc(N2CCN(c3cncc(C4CC(C)(C(N)=O)c5cc([C]=O)ccc5N4)c3)CC2)c(C)c1

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.33
▸ HTT P42858 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ LMNA P02545 4/20 0.31
▸ TP53 P04637 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ MMP2 P08253 1/20 0.31
▸ MMP13 P45452 1/20 0.31
▸ HTR7 P34969 1/20 0.31
▸ TSHR P16473 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11026606 0.86 MKNK1 (0.35) MAPTMEN1KMT2A
SCHEMBL11027123 0.81 MAPT (0.36) MAPTHTTALDH1A1POLBLMNA
SCHEMBL11025741 0.79 POLB (0.38) MAPTHTTALDH1A1POLBLMNA
SCHEMBL11029248 0.76 F7 (0.35) ALDH1A1TSHRHPGD
SCHEMBL11027058 0.75 MAPT (0.46) MAPTALDH1A1LMNATP53SMN1; SMN2
SCHEMBL11024311 0.74 MMP2 (0.38) MAPTHTTPOLBLMNATP53
SCHEMBL11025707 0.74 CYP2C19 (0.40) MAPTHTTALDH1A1LMNAMEN1
SCHEMBL11940902 0.73 SCN9A (0.40) MAPTTP53MMP2MMP13HTR7
SCHEMBL14331324 0.72 HTT (0.35) MAPTHTTALDH1A1POLBLMNA
SCHEMBL11028239 0.68 MAPT (0.36) MAPTHTTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US claimed
EP-2668165-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 — — EP claimed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO claimed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US claimed
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US disclosed
EP-2668165-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 — — EP disclosed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A MAPT 3428/4885HTT 1587/4885ALDH1A1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback